Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07359820 · ClinicalTrials.gov registry record · Phase 2
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
A Phase 2 study, sponsored by Elevar Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07359820 is a Phase 2 study that is actively recruiting participants, run by Elevar Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT07359820, a Phase 2 study, is actively recruiting participants, sponsored by Elevar Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor. * Visit the clinic as instructed for checkups and tests. * Keep a diary recording each time a dose of lirafugratinib is taken.
Interventions
- DRUG Lirafugratinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-06-04 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07359820
The ClinicalTrials.gov registry entry for NCT07359820 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elevar Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lirafugratinib is the first listed.
NCT07359820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07359820 about?
NCT07359820 is a clinical study titled "A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement". The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lira...
What is the current status of trial NCT07359820?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-06-04. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07359820?
The interventions under investigation include: Lirafugratinib (DRUG).
Who is sponsoring clinical trial NCT07359820?
This trial is sponsored by Elevar Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.